{"success":true,"data":{"pressRelease":{"id":"99500","rtpr_id":"nACSHtXgFa","ticker":"PODD","exchange":"NASDAQ","all_tickers":["PODD"],"title":"$PODD Legal Notice: Insulet Sued on Behalf of Investors Over Misstatements Tied to Safety Issues","author":"ACCESSWIRE","published_at":"2026-07-27T19:46:00.897Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n27, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/o8co) announces that a class action lawsuit has been filed\nagainst Insulet Corporation (NASDAQ:PODD) and certain of the Company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Insulet, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nKey Details of the Insulet ($PODD) Class Action:\n*\nLead Plaintiff Deadline: August 31, 2026\n*\nAlleged Misconduct: Securities fraud relating to the safety of Insulet's\nOmnipod products\n*\nLargest Alleged Stock Drop: March 12, 2026 - 6.88% Stock Drop\n*\nCourt: U.S. District Court for the District of Massachusetts\n*\nTake Action: Contact BFA Law (https://pr.report/o8cq) to discuss your rights\n\nInsulet investors have until August 31, 2026 to ask the Court to be appointed\nto lead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Insulet securities. The class action is pending in the U.S. District Court\nfor the District of Massachusetts. It is captioned Hu v. Insulet Corporation\net al., No. 26-cv-13062.\n\nWhy is Insulet Being Sued for Securities Fraud?\n\nInsulet is primarily engaged in the development, manufacture, and sale of\ninsulin delivery systems for people with insulin-dependent diabetes through\nits Omnipod platform. The Omnipod platform includes: the Omnipod® 5 Automated\nInsulin Delivery System (\"Omnipod 5\"), the Omnipod DASH® Insulin Management\nSystem (\"Omnipod DASH\"), and the Omnipod Insulin Management System (\"Omnipod\nEros\").\n\nThroughout the relevant period, Insulet misrepresented the safety of its\nOmnipod products as well as its ability to efficiently produce \"medical grade\nquality at consumer electronic scale.\" In reality, certain of Insulet's\nproducts suffered from undisclosed manufacturing defects that put patient\nsafety at risk.\n\nWhy did Insulet's Stock Drop?\n\nOn March 12, 2026, Insulet disclosed that a manufacturing issue with its\nOmnipod® 5 Pods caused a \"tear in the internal tubing that delivers insulin\"\nresulting in insulin being released inside the Pod \"instead of being fully\ninfused into the body as intended.\" Accordingly, Insulet \"initiated a\nvoluntary Medical Device Correction for specific lots of Omnipod® 5 Pods.\"\n\nThis news caused the price of Insulet stock to drop $16.23 per share, or\n6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84\nper share on March 13, 2026.\n\nOn May 26, 2026, Insulet announced another voluntary Medical Device Correction\ndue to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and\nOmnipod Eros systems. It again indicated that the manufacturing issue resulted\nin a tear in the tubing which \"could result in insulin under-delivery.\"\n\nThis news caused the price of Insulet stock to drop $7.79 per share, or 5.07%,\nfrom a closing price of $218.11 per share on May 26, 2026, to $146.01 per\nshare on May 27, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Insulet, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"there is no better service provider in the practice area,\" \"the\ninterest of the client is always front and center,\" and \"there isn't a better\nfirm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar Fonti & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/podd-legal-notice-insulet-sued-on-behalf-of-investors-over-misst-1196917)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSHtXgFa","title":"$PODD Legal Notice: Insulet Sued on Behalf of Investors Over Misstatements Tied to Safety Issues","author":"ACCESSWIRE","ticker":"PODD","created":"2026-07-27T19:46:00.897Z","tickers":["PODD"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n27, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/o8co) announces that a class action lawsuit has been filed\nagainst Insulet Corporation (NASDAQ:PODD) and certain of the Company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Insulet, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nKey Details of the Insulet ($PODD) Class Action:\n*\nLead Plaintiff Deadline: August 31, 2026\n*\nAlleged Misconduct: Securities fraud relating to the safety of Insulet's\nOmnipod products\n*\nLargest Alleged Stock Drop: March 12, 2026 - 6.88% Stock Drop\n*\nCourt: U.S. District Court for the District of Massachusetts\n*\nTake Action: Contact BFA Law (https://pr.report/o8cq) to discuss your rights\n\nInsulet investors have until August 31, 2026 to ask the Court to be appointed\nto lead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Insulet securities. The class action is pending in the U.S. District Court\nfor the District of Massachusetts. It is captioned Hu v. Insulet Corporation\net al., No. 26-cv-13062.\n\nWhy is Insulet Being Sued for Securities Fraud?\n\nInsulet is primarily engaged in the development, manufacture, and sale of\ninsulin delivery systems for people with insulin-dependent diabetes through\nits Omnipod platform. The Omnipod platform includes: the Omnipod® 5 Automated\nInsulin Delivery System (\"Omnipod 5\"), the Omnipod DASH® Insulin Management\nSystem (\"Omnipod DASH\"), and the Omnipod Insulin Management System (\"Omnipod\nEros\").\n\nThroughout the relevant period, Insulet misrepresented the safety of its\nOmnipod products as well as its ability to efficiently produce \"medical grade\nquality at consumer electronic scale.\" In reality, certain of Insulet's\nproducts suffered from undisclosed manufacturing defects that put patient\nsafety at risk.\n\nWhy did Insulet's Stock Drop?\n\nOn March 12, 2026, Insulet disclosed that a manufacturing issue with its\nOmnipod® 5 Pods caused a \"tear in the internal tubing that delivers insulin\"\nresulting in insulin being released inside the Pod \"instead of being fully\ninfused into the body as intended.\" Accordingly, Insulet \"initiated a\nvoluntary Medical Device Correction for specific lots of Omnipod® 5 Pods.\"\n\nThis news caused the price of Insulet stock to drop $16.23 per share, or\n6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84\nper share on March 13, 2026.\n\nOn May 26, 2026, Insulet announced another voluntary Medical Device Correction\ndue to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and\nOmnipod Eros systems. It again indicated that the manufacturing issue resulted\nin a tear in the tubing which \"could result in insulin under-delivery.\"\n\nThis news caused the price of Insulet stock to drop $7.79 per share, or 5.07%,\nfrom a closing price of $218.11 per share on May 26, 2026, to $146.01 per\nshare on May 27, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Insulet, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"there is no better service provider in the practice area,\" \"the\ninterest of the client is always front and center,\" and \"there isn't a better\nfirm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar Fonti & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/podd-legal-notice-insulet-sued-on-behalf-of-investors-over-misst-1196917)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-07-27T19:46:00.949698232Z","server_sent_at_ms":1785181560949},"received_at":"2026-07-27T19:46:01.000Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/podd-legal-notice-insulet-sued-on-behalf-of-investors-over-misst-1196917"},"analysis":{"id":"88538","press_release_id":"99500","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Insulet Corporation, alleging securities fraud related to the safety of its Omnipod products.\n\nThe lawsuit follows Insulet's disclosures of manufacturing defects in its Omnipod 5 Pods that caused tubing tears, leading to stock drops of 6.88% in March and 5.07% in May.\n\nInvestors have until August 31, 2026, to seek appointment as lead plaintiff; the firm is soliciting shareholders on a contingency basis.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Adam McCall","role":"Contact"}],"products":["Omnipod 5 Automated Insulin Delivery System","Omnipod DASH Insulin Management System","Omnipod Insulin Management System"],"companies":[{"name":"Insulet Corporation","ticker":"PODD","relationship":"defendant"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$16.23 per share","context":"stock drop on March 12, 2026"},{"amount":"$236.07 per share","context":"closing price on March 12, 2026"},{"amount":"$219.84 per share","context":"closing price on March 13, 2026"},{"amount":"$7.79 per share","context":"stock drop on May 26, 2026"},{"amount":"$218.11 per share","context":"closing price on May 26, 2026"},{"amount":"$146.01 per share","context":"closing price on May 27, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Routine lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"PODD"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Insulet Corporation, alleging securities fraud related to the safety of its Omnipod products.\n\nThe lawsuit follows Insulet's disclosures of manufacturing defects in its Omnipod 5 Pods that caused tubing tears, leading to stock drops of 6.88% in March and 5.07% in May.\n\nInvestors have until August 31, 2026, to seek appointment as lead plaintiff; the firm is soliciting shareholders on a contingency basis.","key_figures":{},"named_entities":{"people":[{"name":"Adam McCall","role":"Contact"}],"products":["Omnipod 5 Automated Insulin Delivery System","Omnipod DASH Insulin Management System","Omnipod Insulin Management System"],"companies":[{"name":"Insulet Corporation","ticker":"PODD","relationship":"defendant"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$16.23 per share","context":"stock drop on March 12, 2026"},{"amount":"$236.07 per share","context":"closing price on March 12, 2026"},{"amount":"$219.84 per share","context":"closing price on March 13, 2026"},{"amount":"$7.79 per share","context":"stock drop on May 26, 2026"},{"amount":"$218.11 per share","context":"closing price on May 26, 2026"},{"amount":"$146.01 per share","context":"closing price on May 27, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-27T20:12:33.557Z","global_importance":15,"audience_relevance":10,"importance_components":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":262685,"modelName":"glm-4.7"}}